You can buy or sell ATRA and other stocks, options, ETFs, and crypto commission-free!
Atara Biotherapeutics, Inc. operates as a clinical stage company which focuses on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. Its product candidates are biologics targeting myostatin and activin, members of the transforming growth factor-beta, protein superfamily, which play roles in the growth and maintenance of muscle and many other body tissues. Read More The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.
South San Francisco, California
52 Week High
52 Week Low
Simply Wall StMar 2
Atara Biotherapeutics, Inc. (NASDAQ:ATRA): What Can We Expect From This High Growth Stock?
Atara Biotherapeutics, Inc.’s (NASDAQ:ATRA) latest earnings update in December 2018 confirmed that losses became smaller relative to the prior year’s level as a result of recent tailwinds Below, I’ve laid out key growth figures on how market analysts perceive Atara Biotherapeutics’s earnings growth trajectory over the next couple of years and whether the future looks brighter. I will be looking at earnings excluding extraordinary items to exclude one-off activities to get a better understanding of the under...
Form 8-K Atara Biotherapeutics, For: Feb 26
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2019 Atara Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36548 46-0920988 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 611 Gateway Boulevard, Suite 900 South San Francis...
Stock Price, News, & Analysis for Atara Biotherapeutics
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. It is a...
Expected May 7, Pre-Market